Liberty Dialysis South Ogden Home is a medicare approved dialysis facility center in Ogden, Utah and it has 1 dialysis stations. It is located in Weber county at 475 East 40th Street, Ogden, UT, 84403. You can reach out to the office of Liberty Dialysis South Ogden Home at (801) 627-2886. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Liberty Dialysis South Ogden Home has the following ownership type - Profit. It was first certified by medicare in August, 2016. The medicare id for this facility is 462547 and it accepts patients under medicare ESRD program.
| Name | Liberty Dialysis South Ogden Home |
|---|---|
| Location | 475 East 40th Street, Ogden, Utah |
| No. of Dialysis Stations | 1 |
| Medicare ID | 462547 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 475 East 40th Street, Ogden, Utah, 84403 | |
| (801) 627-2886 | |
| Not Available |
News Archive
What if a smartphone app could help you avoid relapsing back to smoking even before you knew you were at risk? A researcher from the Oklahoma Tobacco Research Center at the Stephenson Cancer Center is developing smartphone-based technology to help people receive real-time tobacco cessation treatment when they are most at risk.
A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
› Verified 1 days ago
| NPI Number | 1770951030 |
| Doing Business As | Liberty Dialysis-weber County, Llc |
| Address | 475 East 40th St South Ogden, Utah, 84403 |
| Phone Number | (801) 627-2886 |
News Archive
What if a smartphone app could help you avoid relapsing back to smoking even before you knew you were at risk? A researcher from the Oklahoma Tobacco Research Center at the Stephenson Cancer Center is developing smartphone-based technology to help people receive real-time tobacco cessation treatment when they are most at risk.
A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 9 |
News Archive
What if a smartphone app could help you avoid relapsing back to smoking even before you knew you were at risk? A researcher from the Oklahoma Tobacco Research Center at the Stephenson Cancer Center is developing smartphone-based technology to help people receive real-time tobacco cessation treatment when they are most at risk.
A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 45 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 371 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 77 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
What if a smartphone app could help you avoid relapsing back to smoking even before you knew you were at risk? A researcher from the Oklahoma Tobacco Research Center at the Stephenson Cancer Center is developing smartphone-based technology to help people receive real-time tobacco cessation treatment when they are most at risk.
A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Liberty Dialysis South Ogden Home with elevated calcium levels.
| Patients with hypercalcemia | 45 |
| Hypercalcemia patient months | 371 |
| Patients with Serumphosphor | 43 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 12 |
News Archive
What if a smartphone app could help you avoid relapsing back to smoking even before you knew you were at risk? A researcher from the Oklahoma Tobacco Research Center at the Stephenson Cancer Center is developing smartphone-based technology to help people receive real-time tobacco cessation treatment when they are most at risk.
A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 22 |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
What if a smartphone app could help you avoid relapsing back to smoking even before you knew you were at risk? A researcher from the Oklahoma Tobacco Research Center at the Stephenson Cancer Center is developing smartphone-based technology to help people receive real-time tobacco cessation treatment when they are most at risk.
A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
› Verified 1 days ago